Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic lupus erythematosus
•
Pediatric Rheumatology
In patients with possible early SLE or undifferentiated disease can multiomics be used to help predict what disease phenotype they will develop?
Related Questions
Would you consider combination belimumab and anakinra for a patient who has SLE and MAS?
What is your approach to screening patients with sJIA for associated lung disease?
What is your approach to the management of shrinking lung syndrome in SLE?
What factors drive you to prioritize treatments that inhibit T cells vs B cell depletion when choosing therapies for patients with refractory SLE?
Where do you introduce SGLT2 and GLP1 medications in the sequence of treatments for patients with lupus nephritis?
What are some of the biggest challenges you run into when patients transition from pediatric to adult care?
How would you approach management of a young male patient with discoid lupus who has had minimal response to hydroxychloroquine (and subtherapeutic whole blood levels) who continues to use tobacco products?
Should the age at which patients transition from pediatric to adult care differ depending on the disease diagnosis?
How do you discuss sexual health with pediatric patients transitioning to adult rheumatology care when the patient is accompanied by parents or caregiver?
How do you envision incorporating CAR-T therapy into your clinical practice?
